ANI Pharmaceuticals (FRA:BSFA) Buildings And Improvements : €0.0 Mil (As of Mar. 2025)

View and export this data going back to 2004. Start your Free Trial

What is ANI Pharmaceuticals Buildings And Improvements?

ANI Pharmaceuticals's quarterly buildings and improvements increased from Sep. 2024 (€0.0 Mil) to Dec. 2024 (€23.3 Mil) but then declined from Dec. 2024 (€23.3 Mil) to Mar. 2025 (€0.0 Mil).

ANI Pharmaceuticals's annual buildings and improvements increased from Dec. 2022 (€15.7 Mil) to Dec. 2023 (€16.4 Mil) and increased from Dec. 2023 (€16.4 Mil) to Dec. 2024 (€23.3 Mil).

ANI Pharmaceuticals Buildings And Improvements Historical Data

The historical data trend for ANI Pharmaceuticals's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ANI Pharmaceuticals Buildings And Improvements Chart

ANI Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Buildings And Improvements

Get a 7-Day Free Trial

9.56

17.67

15.73

16.39

23.34

ANI Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	23.34	-

ANI Pharmaceuticals Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

ANI Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ANI Pharmaceuticals Inc (FRA:BSFA) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

ANIP:USA BSFA:Germany

Address

210 Main Street West, Baudette, MN, USA, 56623

Website

https://www.anipharmaceuticals.com

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

ANI Pharmaceuticals Headlines

No Headlines